• Activity INFORMATION

  Overview

  Buprenorphine is perhaps the most highly misunderstood medication of our time, or at least within the pain management pharmacological treatment options. Being utilized within the indications of pain management and opioid use disorder (opioid addiction) certainly propels it to the top of any polarized discussions to say the least. So how does one navigate through the pharma-sea of opinions? Join us for a dynamic discussion on the complicated simplicities of buprenorphine pharmacology including partial mu opioid agonism, mu opioid receptor affinity, half-life related dosage selections, CYP-450 metabolism and respective interactions, maximum dosage recommendations, morphine milligram equivalent (MME) calculations, and the infamous respiratory depression relative ceiling effects. Dispelling every rumor, one pharmacological principal at a time, helping you help your patients every day.
  

  Handouts

  • Slide Document :   21227H08_2pp.pdf Download

  • Slide Document :   21227H08_6pp.pdf Download

  Financial Support By

  PharmCon

• Learning OBJECTIVES

  Pharmacist

  Recall buprenorphine’s pharmacological properties relevant to patient care including CYP-3A4 interactions, long half-life, maximum recommended dosage, and morphine milligram equivalency.

  Describe buprenorphine’s atypical prescription opioid mechanism of action as a partial mu opioid agonist with greater than average mu opioid receptor affinity and relative respiratory depression ceiling effect.

  Differentiate buprenorphine prescription products by FDA approved indications for pain management and opioid use disorder.

  Pharmacy Technician

  Recall buprenorphine’s pharmacological properties relevant to patient care including CYP-3A4 interactions, long half-life, maximum recommended dosage, and morphine milligram equivalency.

  Describe buprenorphine’s atypical prescription opioid mechanism of action as a partial mu opioid agonist with greater than average mu opioid receptor affinity and relative respiratory depression ceiling effect.

  Differentiate buprenorphine prescription products by FDA approved indications for pain management and opioid use disorder.

• Activity ACCREDITATION

  Activity Type

  Knowledge

  CE Broker

  20-858843

  Universal Activity Number

  Pharmacist 0798-0000-21-227-H08-P
  Pharmacy Technician 0798-0000-21-227-H08-T
  

  PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

  PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

  In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

• Activity INSTRUCTION

  Faculty

  Mark  Garofoli, PharmD, MBA, BCGP, CPE, CTTS Assistant Professor, West Virginia University School of Pharmacy

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).